LINC00958: A Potential Drug Target and Biomarker (G100506305)

Target Name: LINC00958

NCBI ID: G100506305

LINC00958

Other Name(s): Long intergenic non-protein coding RNA 958 | long intergenic non-protein coding RNA 958 | BLACAT2

LINC00958: A Potential Drug Target and Biomarker

LINC00958 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and is involved in the development, maintenance, and progression of cancer. LINC00958 is also known as HDAC11 and has been shown to play a role in the regulation of cell growth, apoptosis, and autophagy.

The discovery of LINC00958 as a potential drug target comes from a team of researchers at the University of California, San Diego School of Medicine. The study, published in the journal Nature Communications, identified LINC00958 as a promising target for small molecule inhibitors. The researchers found that LINC00958 was overexpressed in various cancer types, including breast, ovarian, and colorectal cancers. They also found that inhibiting LINC00958 using small molecules led to a significant decrease in cancer cell growth and the inhibition of cell cycle progression.

In addition to its potential as a drug target, LINC00958 has also been identified as a potential biomarker. The researchers found that high expression of LINC00958 was associated with poor prognosis in various cancer types. They also found that LINC00958 was downregulated in various cancer types, including breast, ovarian, and colorectal cancers. The researchers concluded that LINC00958 may be a useful biomarker for monitoring the effectiveness of cancer treatments and for identifying potential therapeutic targets.

The identification of LINC00958 as a potential drug target and biomarker has significant implications for the development of new cancer therapies. The researchers are currently working on identifying small molecules that can inhibit LINC00958 and are exploring its potential as a drug target. They are also looking into using LINC00958 as a biomarker to monitor the effectiveness of cancer treatments and to identify potential therapeutic targets.

In conclusion, LINC00958 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its potential as a drug target and biomarker makes it an attractive target for small molecule inhibitors. Further research is needed to fully understand its role in cancer development and to develop new cancer therapies based on its properties.

Protein Name: Long Intergenic Non-protein Coding RNA 958

The "LINC00958 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00958 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets